Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2024-11-07 Earnings Release
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 revenue guidance adjusted
Earnings Release Classification · 1% confidence The document explicitly reports financial results for the first nine months of 2024 ("9M 2024"), including revenue, EBITDA, and net results, and provides condensed financial statements (Income Statement, Statement of Financial Position, Cash Flow). It also mentions an adjustment to the full-year revenue forecast. This content structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year. The key terms are "9M 2024", "Interim Statement", and the inclusion of detailed, though unaudited, financial tables. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains detailed financial tables and statements, not just highlights. It is also not a 10-K (Annual Report). 9M 2024
2024-11-07 English
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentivas public tender offer
M&A Activity Classification · 1% confidence The document is a news release dated October 30, 2024, announcing that the Management Board and Supervisory Board of APONTIS PHARMA AG have published their joint reasoned statement recommending shareholders accept a public tender offer from Zentiva AG. The key phrases are 'public tender offer,' 'joint reasoned statement,' and the context is a takeover/acquisition scenario. This type of announcement, detailing the board's opinion on a takeover bid, falls under Merger & Acquisition (M&A) activity. The specific code for M&A Activity is TAR.
2024-10-30 English
APONTIS PHARMA and Zentiva entered into partnership for future growth Zentiva will launch a voluntary public purchase offer
M&A Activity Classification · 1% confidence The document is a press release announcing that Zentiva will launch a voluntary public purchase offer for APONTIS PHARMA shares. Key phrases include 'voluntary public purchase offer', 'Tender Offer' (as a keyword), 'Offer Price', and details about securing a stake from the main shareholder. This clearly describes a takeover or acquisition proposal, which aligns with the definition for M&A Activity (TAR). It is not a standard financial report (10-K, IR, ER) or a simple announcement of a report (RPA).
2024-10-16 English
APONTIS PHARMA and Zentiva enter into investment agreement Zentiva will launch a voluntary public purchase offer
Delisting Announcement Classification · 1% confidence The document is an 'Ad-hoc' announcement dated October 16, 2024, disclosing 'inside information' pursuant to Article 17 MAR. The core content describes an 'investment agreement' where Zentiva will launch a 'voluntary public purchase offer' for all outstanding shares of APONTIS PHARMA. This clearly indicates an announcement related to a takeover bid or merger proposal. Based on the provided definitions, the most appropriate classification is 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids. Although it is a regulatory announcement (RNS), TAR is more specific to the subject matter.
2024-10-16 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Governance Information Classification · 1% confidence The document is a 'Bericht des Aufsichtsrats' (Report of the Supervisory Board) for APONTIS PHARMA AG for the fiscal year 2023. It details the board's activities, committee meetings, corporate governance, risk management, and strategic oversight. While it is part of the annual reporting package, it is a specific governance report rather than the full 10-K (Annual Report) or a standalone financial statement. According to the provided categories, this fits best under Governance Information (CGR), as it focuses on board structure, internal rules, and oversight activities. FY 2023
2024-09-13 German
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 forecast for the full year confirmed
Earnings Release Classification · 1% confidence The document explicitly contains the keyword 'Half Year Report/Half Year Results' in its metadata/header section (EQS-News). It details financial performance metrics (Revenue, EBITDA, Net result) specifically for 'H1 2024' and compares them to 'H1 2023'. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). It is not an Earnings Release (ER) because it includes detailed, unaudited consolidated financial statements (Income Statement, Statement of Financial Position, Cash Flow Statement), making it more comprehensive than just key highlights. H1 2024
2024-08-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.